Infectious complications after autologous peripheral blood progenitor cell transplantation followed by G-CSF

被引:0
作者
M Offidani
L Corvatta
A Olivieri
S Rupoli
J Frayfer
A Mele
E Manso
M Montanari
R Centurioni
P Leoni
机构
[1] Ancona University School of Medicine,Department of Hematology
[2] Torrette Hospital,Department of Microbiology
来源
Bone Marrow Transplantation | 1999年 / 24卷
关键词
infections; peripheral blood progenitor cell transplantation; mucositis; neutropenia; antimicrobial prophylaxis;
D O I
暂无
中图分类号
学科分类号
摘要
Infectious complications after autologous peripheral blood progenitor cell transplantation (PBPCT) have been reported in a few studies including small patient numbers. The present study was performed to assess the incidence, types, outcome and factors affecting early and late infections in 150 patients aged 18 to 68 years (median 46.5) who underwent high-dose therapy, with G-CSF. Patients were kept in reverse isolation rooms and received antimicrobial chemoprophylaxis with oral quinolone and fluconazole. One hundred and fifteen patients (76.7%) developed fever (median 3 days, range 1–29); 20 patients (55.5%) had Gram-positive and 13 (36.2%) Gram-negative bacterial infections. There were no fungal infections or infection-related deaths. Mucositis grade II–IV (P = 0.0001; odds ratio 3.4) and >5 days on ANC<100/μl (P = 0.0001; odds ratio 2.3) correlated with development of infection. Only days with ANC <100/μl affected infection outcome (P = 0.0024) whereas the antibiotic regimen did not. After day +30 there were four cases of bacterial pneumonitis (2.7%), one case of fatal CMV pneumonia (0.8%) and 20 of localized VZV infection (13.3%). Reduction of neutropenia duration with PBPCT and G-CSF is not enough to prevent early infectious complications since only a few days of severe neutropenia and mucositis are related to development of early infections. However, no infection-related deaths were seen. Although Gram-positive organisms were the major cause of bacteremia, a glycopeptide in the empirical antibiotic regimen did not affect infection outcome. In PBPCT recipients, early and late opportunistic infections were notably absent, which was at variance with what was seen with bone marrow recipients. Efforts should be made to prevent mucositis and neutropenia and identify new strategies of antibacterial prophylaxis.
引用
收藏
页码:1079 / 1087
页数:8
相关论文
共 50 条
  • [31] Does Mesenchymal Stromal Cell Count in Pre-autologous Hematopoietic Stem Cell Transplant Peripheral Blood and Apheresis Product Predict for Infectious Complications in the Post-transplant Period?
    Ankur Jain
    Alka Khadwal
    Man Updesh Singh Sachdeva
    Praveen Bose
    Deepesh Lad
    Shalmoli Bhattacharya
    Gaurav Prakash
    Pankaj Malhotra
    Neelam Varma
    Subhash Varma
    Indian Journal of Hematology and Blood Transfusion, 2021, 37 : 484 - 488
  • [32] RECOMBINANT HUMAN G-CSF (LENOGRASTIM) FOR INFECTIOUS COMPLICATIONS IN GLYCOGEN-STORAGE-DISEASE TYPE-IB - REPORT OF 7 CASES
    DONADIEU, J
    BADERMEUNIER, B
    BERTRAND, Y
    LACHAUX, A
    LABRUNE, P
    GOUGEROTPOCIDALO, MA
    ODIEVRE, M
    GIBEAUD, P
    YVER, A
    TCHERNIA, G
    GRISCELLI, C
    DOMMERGUES, JP
    NOUVELLE REVUE FRANCAISE D HEMATOLOGIE, 1993, 35 (06): : 529 - 534
  • [33] Sexual dysfunction in females treated with peripheral blood progenitor cell transplantation: review of literature
    Slovacek, L.
    Slanska, I
    Slovackova, B.
    Priester, P.
    Kopecky, J.
    Jebavy, L.
    BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY, 2010, 111 (08): : 457 - 460
  • [34] High-dose therapy with peripheral blood progenitor cell transplantation in multiple myeloma
    Goldschmidt, H
    Hegenbart, U
    Wallmeier, M
    Hohaus, S
    Engenhart, R
    Wannenmacher, M
    Haas, R
    ANNALS OF ONCOLOGY, 1997, 8 (03) : 243 - 246
  • [35] INFECTIOUS COMPLICATIONS AND THEIR CONTRIBUTING RISK FACTORS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
    Akhmedov, M., I
    Klyasova, G. A.
    Parovichnikova, E. N.
    GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2022, 67 (01): : 90 - 107
  • [36] Complications after high-dose therapy and autologous blood stem cell transplantation: Retrospective analysis in a cohort of unselected patients
    Hoffmann, M
    Henrich, D
    Hackenberg, U
    Mewes, D
    Hellstern, P
    Uppenkamp, M
    MEDIZINISCHE KLINIK, 2001, 96 (04) : 196 - 201
  • [37] Autologous blood stem cell transplantation for Hodgkin and non-Hodgkin lymphoma: Complications and outcome
    Kumar, Lalit
    Ganessan, Prasanth
    Ghosh, Indraneel
    Panda, Deepanjan
    Gogia, Ajay
    Mandhania, Sushil
    NATIONAL MEDICAL JOURNAL OF INDIA, 2010, 23 (06) : 330 - 335
  • [38] Glutamine-enriched parenteral nutrition after autologous peripheral blood stem cell transplantation:: effects on immune reconstitution and mucositis
    Piccirillo, N
    De Matteis, S
    Laurenti, L
    Chiusolo, P
    Sorà, F
    Pittiruti, M
    Rutella, S
    Cicconi, S
    Fiorini, A
    D'Onofrio, G
    Leone, G
    Sica, S
    HAEMATOLOGICA, 2003, 88 (02) : 192 - 200
  • [39] Comparison of lenograstim and filgrastim on haematological effects after autologous peripheral blood stem cell transplantation with high-dose chemotherapy
    Kim, IH
    Park, SK
    Suh, OK
    Oh, JM
    CURRENT MEDICAL RESEARCH AND OPINION, 2003, 19 (08) : 753 - 759
  • [40] Phase 1 study of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in breast cancer patients after autologous peripheral blood progenitor cell (PBPC) transplantation
    B Bolwell
    J Vredenburgh
    B Overmoyer
    C Gilbert
    L Chap
    DM Menchaca
    S Cruickshank
    J Glaspy
    Bone Marrow Transplantation, 2000, 26 : 141 - 145